ID   OS-RC-2
AC   CVCL_1626
SY   OSRC2; RC-2
DR   BTO; BTO:0002403
DR   CLO; CLO_0050889
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472222
DR   BioSample; SAMN10987712
DR   CCRID; 1101HUM-PUMC000292
DR   CCRID; 3101HUMTCHu40
DR   Cell_Model_Passport; SIDM00239
DR   ChEMBL-Cells; CHEMBL3308274
DR   ChEMBL-Targets; CHEMBL2366188
DR   Cosmic; 909250
DR   Cosmic-CLP; 909250
DR   DepMap; ACH-000159
DR   EGA; EGAS00001000978
DR   GDSC; 909250
DR   GEO; GSM1670310
DR   IARC_TP53; 21604
DR   KCB; KCB 200779YJ
DR   LiGeA; CCLE_815
DR   LINCS_LDP; LCL-1768
DR   PharmacoDB; OSRC2_1203_2019
DR   Progenetix; CVCL_1626
DR   RCB; RCB0735
DR   Wikidata; Q54936539
RX   PubMed=4008433;
RX   PubMed=14534724;
RX   PubMed=15604581;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~60 hours, at 30th passage (PubMed=4008433).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys211Serfs (c.631_634+12del16); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.1%; Native American=0%; East Asian, North=77.03%; East Asian, South=20.25%; South Asian=0%; European, North=0.95%; European, South=1.66% (PubMed=30894373).
CC   Derived from sampling site: Kidney.
ST   Source(s): CCRID; Cosmic-CLP; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 8,12
ST   D16S539: 11
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 31.2
ST   D2S1338: 20
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 24
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 30
//
RX   PubMed=4008433; DOI=10.1007/BF02620929;
RA   Kinouchi T., Kotake T., Mori Y., Abe T.;
RT   "Human renal cell carcinoma: establishment and characterization of a
RT   new cell line (OS-RC-2).";
RL   In Vitro Cell. Dev. Biol. 21:195-199(1985).
//
RX   PubMed=14534724; DOI=10.3892/or.10.6.1947;
RA   Ikemoto S., Narita K., Yoshida N., Wada S., Kishimoto T., Sugimura K.,
RA   Nakatani T.;
RT   "Effects of tumor necrosis factor alpha in renal cell carcinoma.";
RL   Oncol. Rep. 10:1947-1955(2003).
//
RX   PubMed=15604581; DOI=10.1159/000081597;
RA   Ikemoto S., Sugimura K., Yoshida N., Kuratsukuri K., Wada S.,
RA   Nakatani T.;
RT   "Comparative antitumor activity of 5-fluorouracil and
RT   5'-deoxy-5-fluorouridine in combination with interferon-alpha in
RT   renal cell carcinoma cell lines.";
RL   Urol. Int. 73:348-353(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//